BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Navarro-almenzar B, Cerezo-manchado JJ, Caro-martinez C, García-candel F, Flores Blanco PJ, Ruiz GE, Andreu Cayuelas JM, Montoya FA, Cascales A, Lova Navarro A, García Alberola A, Andrés Pascual Figal D, Bailen Lorenzo JL, Manzano-fernández S. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry. Current Medical Research and Opinion 2019;35:2035-41. [DOI: 10.1080/03007995.2019.1647735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Zeymer U, Lober C, Wolf A, Richard F, Schäfer H, Taggeselle J, Kabitz HJ, Prondzinsky R, Süselbeck T; APAF-Investigators. Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry. Cardiol Ther 2020;9:467-78. [PMID: 32638266 DOI: 10.1007/s40119-020-00188-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wu X, Hu L, Liu J, Gu Q. Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. Front Cardiovasc Med 2021;8:724301. [PMID: 34568462 DOI: 10.3389/fcvm.2021.724301] [Reference Citation Analysis]
3 Salameh M, Gronich N, Stein N, Kotler A, Rennert G, Auriel E, Saliba W. Stroke and Bleeding Risks in Patients with Atrial Fibrillation Treated with Reduced Apixaban Dose: A Real‐Life Study. Clin Pharmacol Ther 2020;108:1265-73. [DOI: 10.1002/cpt.1952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bo M, Corsini A, Brunetti E, Isaia G, Gibello M, Ferri N, Poli D, Marchionni N, De Ferrari GM. Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. Eur Heart J Cardiovasc Pharmacother 2021;7:334-45. [PMID: 32853346 DOI: 10.1093/ehjcvp/pvaa103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Navarro-Almenzar B, Cerezo-Manchado JJ, García-Candel F. Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity. Int J Cardiol Heart Vasc 2021;37:100913. [PMID: 34825048 DOI: 10.1016/j.ijcha.2021.100913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gedikli Ö, Altay S, Ünlü S, Çakmak HA, Aşkın L, Yanık A, Beşli F, Sinan ÜY, Canpolat U, Şahin M, Pehlivanoğlu S. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study. Anatol J Cardiol 2021;25:196-204. [PMID: 33690135 DOI: 10.5152/AnatolJCardiol.2021.57635] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shen NN, Zhang C, Hang Y, Li Z, Kong LC, Wang N, Wang JL, Gu ZC. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis. Front Pharmacol 2021;12:581293. [PMID: 34122056 DOI: 10.3389/fphar.2021.581293] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu X, Huang M, Ye C, Xiao X, Yan C. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis. Clin Cardiol 2021;44:472-80. [PMID: 33682184 DOI: 10.1002/clc.23586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]